TScan Therapeutics (TCRX) Financials: Revenue & Earnings

TCRX price $0.19 -0.00 -0.16%

Ticker
TCRX
Price
$0.19
Change
-0.00 -0.16%
Market cap ?
$12.17M
P/E ?
-0.20
Dividend yield ?
0.00%
Beta ?
1.14
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
56
Value
59
Quality
46
Growth
62

Stocklytics score rationale: value 59, quality 46, growth 62.

Financials

2019202020212022202320242025
01085000101410001353500021049000281600010325000

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell…

Fair value

TCRX fair value Not meaningful. Price $0.19.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare TCRX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-11—-0.18—459.00K
2026-08-12-0.23-0.251.05M1.88M
2026-05-06-0.22-0.22982.00K2.50M
2026-03-04-0.18-0.272.57M2.44M
2025-11-12-0.28-0.352.51M1.94M
2025-08-12-0.28-0.283.08M1.86M
2025-05-06-0.26-0.282.17M1.08M
2025-03-05-0.29-0.27665.00K1.52M
2024-11-12-0.25-0.281.05M1.17M
2024-08-12-0.28-0.30536.00K1.80M
2024-05-13-0.32-0.25566.00K3.98M
2024-03-06-0.21-0.307.21M3.45M
2023-11-09-0.24-0.433.89M4.45M
2023-08-10-0.51-0.763.15M4.37M
2023-05-10-0.93-0.736.80M4.87M
2023-03-08-0.78-0.731.00K4.10M
2022-11-09-0.67-0.733.36M3.93M
2022-08-10-0.63-0.764.06M3.00M
2022-05-09-0.67-0.693.02M2.76M
2022-03-09-0.38-0.732.85M3.47M
2021-11-10-0.80-0.682.41M6.70M
2021-08-19-7.69-2.872.85M2.43M
2021-07-15-0.32—2.03M—
2020-12-31-0.33—795.00K—
2020-09-30-0.30—290.00K—
2020-06-30-0.23———
2020-03-31-0.23———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-01MacBeath GavinBuy1.00M——
2026-10-01ZDRAVESKI ZORANBuy300.00K——
2026-05-20BAKER BROS. ADVISORS LPBuy67.00K$0.9966.64K
2026-05-20Woods KeithBuy67.00K$0.9966.64K
2026-05-20Nicholson Garry ABuy67.00K$0.9966.64K
2026-05-20Gruia GabrielaBuy67.00K$0.9966.64K
2026-05-20Dorton KatinaBuy67.00K$0.9966.64K
2026-05-20Klencke BarbaraBuy67.00K$0.9966.64K
2026-01-20Amello JasonBuy350.00K$1.12392.00K
2026-01-20MacBeath GavinBuy1.17M$1.121.30M
2026-01-20Dworak LeidenBuy100.00K$1.12112.00K
2026-01-20Louis ChrystalBuy420.00K$1.12470.40K
2026-01-20ZDRAVESKI ZORANBuy350.00K$1.12392.00K
2025-12-23Lynx1 Capital Management LPBuy6.23K$0.905.60K
2025-12-22Lynx1 Capital Management LPBuy75.50K$0.9067.95K
2025-12-19Lynx1 Capital Management LPBuy80.07K$0.9071.97K
2025-08-14Dworak LeidenOther46.88K$6.00281.25K
2025-08-14Dworak LeidenOther25.00K$2.2355.75K
2025-08-14Dworak LeidenOther70.00K$3.06214.55K
2025-08-14Dworak LeidenOther163.80K$2.49407.86K
2025-08-14Dworak LeidenOther23.75K$1.8142.99K
2025-08-14Dworak LeidenOther37.50K$2.90108.75K
2025-06-30BAKER BROS. ADVISORS LPBuy67.00K$1.4597.15K
2025-06-30Klencke BarbaraBuy67.00K$1.4597.15K
2025-06-30Nicholson Garry ABuy67.00K$1.4597.15K
2025-06-30Woods KeithBuy67.00K$1.4597.15K
2025-06-30Dorton KatinaBuy67.00K$1.4597.15K
2025-06-30Gruia GabrielaBuy67.00K$1.4597.15K
2025-05-20Lynx1 Capital Management LPBuy1.20M$1.201.44M
2025-05-19Lynx1 Capital Management LPBuy1.39M$1.201.67M
2025-01-03ZDRAVESKI ZORANBuy250.00K$3.06766.25K
2025-01-03MacBeath GavinBuy800.00K$3.062.45M
2025-01-03Amello JasonBuy270.00K$3.06827.55K
2025-01-03Louis ChrystalBuy400.00K$3.061.23M
2024-12-26Lynx1 Capital Management LPBuy7.50M$0.00750
2024-12-13Lynx1 Capital Management LPBuy100.00K$2.90290.14K
2024-12-12Lynx1 Capital Management LPBuy31.80K$3.0195.63K
2024-11-15Lynx1 Capital Management LPBuy947$4.344.11K
2024-09-23Klencke BarbaraBuy5.00K$5.2926.45K
2024-08-26Klencke BarbaraBuy5.00K$5.5327.65K
2024-08-23Klencke BarbaraBuy5.00K$5.6928.45K
2024-08-23ZDRAVESKI ZORANSell64.17K$2.49159.77K
2024-08-23ZDRAVESKI ZORANBuy64.17K$2.49159.77K
2024-08-23ZDRAVESKI ZORANBuy13.12K$1.8123.76K
2024-08-23ZDRAVESKI ZORANBuy25.00K$3.2781.75K
2024-08-23ZDRAVESKI ZORANBuy54.90K$4.85266.24K
2024-08-23ZDRAVESKI ZORANSell54.90K$4.85266.24K
2024-08-23ZDRAVESKI ZORANSell25.00K$3.2781.75K
2024-08-23ZDRAVESKI ZORANSell13.12K$1.8123.76K
2024-08-23ZDRAVESKI ZORANSell164.69K$5.78952.12K
2024-06-12Woods KeithBuy47.50K$8.88421.80K
2024-06-12Dorton KatinaBuy47.50K$8.88421.80K
2024-06-12Klencke BarbaraBuy47.50K$8.88421.80K
2024-06-12Gruia GabrielaBuy47.50K$8.88421.80K
2024-06-12Nicholson Garry ABuy47.50K$8.88421.80K
2024-06-12Nicholson Garry ABuy23.75K$8.88210.90K
2024-06-12Nicholson Garry AOther0——
2024-06-12BAKER BROS. ADVISORS LPBuy47.50K$8.88421.80K
2024-05-01Louis ChrystalBuy380.00K$8.623.28M
2024-04-22Louis ChrystalOther0——
2024-04-19BAKER BROS. ADVISORS LPBuy8.85M$0.00885
2024-04-19BAKER BROS. ADVISORS LPBuy825.97K$0.0083
2024-04-19Lynx1 Capital Management LPBuy5.00M$0.00500
2024-02-01Amello JasonBuy750.00K$5.153.86M
2024-01-29Amello JasonOther0——
2024-01-12ZDRAVESKI ZORANBuy52.50K$6.00315.00K
2024-01-12Dworak LeidenBuy46.88K$6.00281.25K
2024-01-12MacBeath GavinBuy160.00K$6.00960.00K
2023-12-19BARBERICH TIMOTHY JBuy317$4.971.58K
2023-12-18BARBERICH TIMOTHY JBuy28.83K$4.89140.88K
2023-12-14Klencke BarbaraBuy5.00K$5.0825.40K
2023-12-06Woods KeithBuy17.50K$6.74117.95K
2023-12-06Woods KeithOther0——
2023-07-21Dworak LeidenBuy25.00K$2.2355.75K
2023-07-21Dworak LeidenSell0——
2023-07-21Dworak LeidenSell37.50K$2.90108.75K
2023-07-21Dworak LeidenSell28.75K$1.8152.04K
2023-07-21Dworak LeidenSell163.80K$2.49407.86K
2023-06-13BARBERICH TIMOTHY JBuy35.00K$2.6693.10K
2023-06-13Barton DeboraBuy430.00K$2.491.07M
2023-06-13Dorton KatinaBuy35.00K$2.6693.10K
2023-06-13Gruia GabrielaBuy35.00K$2.6693.10K
2023-06-13Klencke BarbaraBuy36.52K$2.6697.15K
2023-06-13Silver Brian M.Buy632.50K$2.491.57M
2023-06-13MacBeath GavinBuy1.12M$2.492.79M
2023-06-13ZDRAVESKI ZORANBuy430.00K$2.491.07M
2023-06-13BAKER BROS. ADVISORS LPBuy35.00K$2.6693.10K
2023-06-02BARBERICH TIMOTHY JBuy37.88K$2.6399.56K
2023-06-01BAKER BROS. ADVISORS LPBuy34.31M$0.003.43K
2023-06-01BAKER BROS. ADVISORS LPBuy3.19M$0.00319
2023-05-31Lynx1 Capital Management LPSell10.00K$2.5125.15K
2023-05-31Lynx1 Capital Management LPSell15.00K$2.5237.80K
2023-05-31Lynx1 Capital Management LPSell400$2.511.00K
2023-05-31Lynx1 Capital Management LPOther0——
2023-05-26EcoR1 Capital, LLCOther0——
2023-04-06Klencke BarbaraBuy9.15K$2.2020.12K
2023-04-06Klencke BarbaraOther0——
2023-04-06Klencke BarbaraSell0——
2023-02-02SOUTHWELL DAVID PBuy100.00K$1.81181.00K
2023-02-02MacBeath GavinBuy40.00K$1.8172.40K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 59, holders +1 vs prior quarter. Ownership 27.58%.

HolderSharesChangeChange %Value
LYNX1 CAPITAL MANAGEMENT LP8.02M00.00%7.86M
BVF INC/IL5.56M00.00%5.45M
BAKER BROS. ADVISORS LP2.78M00.00%2.73M
VANGUARD CAPITAL MANAGEMENT LLC2.16M4.58K+0.21%2.12M
TWO SIGMA INVESTMENTS, LP1.95M740.60K+61.26%1.91M
RENAISSANCE TECHNOLOGIES LLC1.33M-37.98K-2.78%1.30M
ACADIAN ASSET MANAGEMENT LLC1.31M1.10M+546.50%1.28M
DEER MANAGEMENT CO. LLC1.25M00.00%1.22M
MILLENNIUM MANAGEMENT LLC1.16M-296.67K-20.32%1.14M
JACOBS LEVY EQUITY MANAGEMENT, INC1.05M241.45K+29.87%1.03M
CITADEL ADVISORS LLC1.01M690.70K+216.92%989.03K
BLACKROCK, INC.994.65K-846.30K-45.97%974.86K
BOOTHBAY FUND MANAGEMENT, LLC772.24K772.24KNew756.87K
MARSHALL WACE, LLP687.36K450.02K+189.60%673.62K
DC FUNDS, LP630.00K00.00%617.46K
GEODE CAPITAL MANAGEMENT, LLC584.81K-32.14K-5.21%573.40K
D. E. SHAW & CO., INC.548.40K228.81K+71.60%537.49K
GSA CAPITAL PARTNERS LLP548.09K169.13K+44.63%537.00K
KALEHUA CAPITAL MANAGEMENT LLC454.88K454.88KNew445.82K
VANGUARD FIDUCIARY TRUST CO363.95K58.18K+19.03%356.68K
JANE STREET GROUP, LLC241.49K97.07K+67.21%236.69K
VERDAD ADVISERS, LP232.76K98.76K+73.70%228.13K
STATE STREET CORP207.31K00.00%203.19K
MIZUHO SECURITIES USA LLC205.60K205.60KNew201.51K
MORGAN STANLEY197.89K24.25K+13.96%193.95K

Earnings and financials

TScan Therapeutics, Inc. (TCRX) trades at $0.19, with a market cap of $12.17M and a trailing P/E of -0.20. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2019202020212022202320242025
01085000101410001353500021049000281600010325000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

TScan Therapeutics (TCRX) Financials: Revenue & Earnings

TCRX$0.19-0.00 -0.16%

$12.17M

Market Cap

-0.20

P/E

—

Forward P/E

56

Score

Price History